EGFR and neoplasm: The EGFR inhibitor erlotinib reduced CD4+ effector regulatory T-cell infiltration in the tumor microenvironment and showed better antitumor effects in combination with αPD-1 monoclonal antibody than either treatment alone (Sugiyama et al. 2020).